Shares of OptiBiotix Health PLC (LON: OPTI) today surged 12.7% after the company’s partner, Seed Health, received regulatory approval to start human trials of its irritable bowel syndrome (IBS) drug.
The US Food & Drug Administration (FDA) gave the go-ahead for Optibiotix’s Lactobacillus Plantarum (LPLDL) probiotic to proceed to human trials after approving Seed Health’s investigational new drug application.
The FDA has allowed the drug dubbed DS-01 to go straight into Phase II clinical trials skipping Phase I trials.
Interested in investing after today’s move?
XTB gives investors access to thousands of UK and international stocks,
including fractional shares from just £1.
Explore stocks with XTB →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to invest in the stocks making the news?
Go from following the market to investing in it, with access to thousands
of stocks across major UK and international markets.
See available stocks →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Own the stocks you’re reading about
Invest in real shares across the UK, US and other major global markets
through XTB, all from one investment account.
Explore XTB shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
You don’t need to buy a whole share
Fractional shares let you invest from just £1, giving you more control
over how much you put into individual companies.
Explore fractional shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to see how XTB works first?
Explore the platform with an XTB demo account before deciding whether
you want to invest with real money.
Try the XTB demo →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
“We are pleased to see that Seed has achieved FDA authorisation for an IND in a product containing OptiBiotix’s lactobacillus plantarum,” said chief executive Stephen O’Hara.
Adding:
“Seed are one of a number of partners OptiBiotix is working with to bring a range of cardiovascular, general health, and IBS applications to supplement and pharmaceutical markets around the world,” he added.
O’Hara also clarified that the FDA has given LPDL the good manufacturing practice accreditation, which “created the potential for it to become a commercialised as a pharmaceutical drug product”.
Optibiotix share price
Optibiotix shares today rallied 12.7% to trade at 62p having risen from Thursday’s closing price of 55p.
People who read this also read:
